These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32934044)

  • 21. The Interplay between Gut Microbiota and the Immune System in Liver Transplant Recipients and Its Role in Infections.
    Ancona G; Alagna L; Lombardi A; Palomba E; Castelli V; Renisi G; Dondossola D; Iavarone M; Muscatello A; Gori A; Bandera A
    Infect Immun; 2021 Oct; 89(11):e0037621. PubMed ID: 34460287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The gut-liver axis and gut microbiota in health and liver disease.
    Hsu CL; Schnabl B
    Nat Rev Microbiol; 2023 Nov; 21(11):719-733. PubMed ID: 37316582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.
    Chen YX; Lai LN; Zhang HY; Bi YH; Meng L; Li XJ; Tian XX; Wang LM; Fan YM; Zhao ZF; Han DW; Ji C
    World J Gastroenterol; 2016 Mar; 22(10):2949-59. PubMed ID: 26973391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Microbiota: What Do We Know about It at Present?
    Derovs A; Laivacuma S; Krumina A
    Medicina (Kaunas); 2019 Aug; 55(8):. PubMed ID: 31405111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
    Zeng Y; Chen S; Fu Y; Wu W; Chen T; Chen J; Yang B; Ou Q
    J Viral Hepat; 2020 Feb; 27(2):143-155. PubMed ID: 31600845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates.
    Khan A; Ding Z; Ishaq M; Bacha AS; Khan I; Hanif A; Li W; Guo X
    Int J Biol Sci; 2021; 17(3):818-833. PubMed ID: 33767591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The gut microbiota-bile acid axis: A potential therapeutic target for liver fibrosis.
    Zhang YL; Li ZJ; Gou HZ; Song XJ; Zhang L
    Front Cell Infect Microbiol; 2022; 12():945368. PubMed ID: 36189347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota.
    Maslennikov R; Alieva A; Poluektova E; Zharikov Y; Suslov A; Letyagina Y; Vasileva E; Levshina A; Kozlov E; Ivashkin V
    World J Gastroenterol; 2023 Jul; 29(27):4236-4251. PubMed ID: 37545638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut.
    Ridlon JM; Kang DJ; Hylemon PB; Bajaj JS
    Dig Dis; 2015; 33(3):338-45. PubMed ID: 26045267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gut Microbiome: A Potential Modifiable Risk Factor in Biliary Atresia.
    Jain V; Alexander EC; Burford C; Verma A; Dhawan A
    J Pediatr Gastroenterol Nutr; 2021 Feb; 72(2):184-193. PubMed ID: 33427793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dysbiosis of skin microbiome and gut microbiome in melanoma progression.
    Mekadim C; Skalnikova HK; Cizkova J; Cizkova V; Palanova A; Horak V; Mrazek J
    BMC Microbiol; 2022 Feb; 22(1):63. PubMed ID: 35216552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microbiota Dysbiosis and Gut Barrier Dysfunction Associated with Non-Alcoholic Fatty Liver Disease Are Modulated by a Specific Metabolic Cofactors' Combination.
    Quesada-Vázquez S; Bone C; Saha S; Triguero I; Colom-Pellicer M; Aragonès G; Hildebrand F; Del Bas JM; Caimari A; Beraza N; Escoté X
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis.
    Shu W; Shanjian C; Jinpiao L; Qishui O
    Ann Hepatol; 2022; 27(2):100676. PubMed ID: 35093600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gut microbiota dysbiosis and Huntington's disease: Exploring the gut-brain axis and novel microbiota-based interventions.
    Sharma G; Biswas SS; Mishra J; Navik U; Kandimalla R; Reddy PH; Bhatti GK; Bhatti JS
    Life Sci; 2023 Sep; 328():121882. PubMed ID: 37356750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gut and oral microbiota in autoimmune liver disease.
    Abe K; Fujita M; Hayashi M; Okai K; Takahashi A; Ohira H
    Fukushima J Med Sci; 2020 Jan; 65(3):71-75. PubMed ID: 31564673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gut microbiota mediated molecular events and therapy in liver diseases.
    Qi X; Yang M; Stenberg J; Dey R; Fogwe L; Alam MS; Kimchi ET; Staveley-O'Carroll KF; Li G
    World J Gastroenterol; 2020 Dec; 26(48):7603-7618. PubMed ID: 33505139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the gut-liver-immune axis to treat cirrhosis.
    Tranah TH; Edwards LA; Schnabl B; Shawcross DL
    Gut; 2021 May; 70(5):982-994. PubMed ID: 33060124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anorexia nervosa and gut microbiome: implications for weight change and novel treatments.
    Wei Y; Peng S; Lian C; Kang Q; Chen J
    Expert Rev Gastroenterol Hepatol; 2022 Apr; 16(4):321-332. PubMed ID: 35303781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in Gut Microbiota of Viral Hepatitis Cirrhosis.
    Wang Y; Pan CQ; Xing H
    Biomed Res Int; 2019; 2019():9726786. PubMed ID: 31886272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.